Ifebemtinib is under clinical development by Inxmed (Nanjing) and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ifebemtinib LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ifebemtinib overview

Ifebemtinib is under development for the treatment of peritoneal cancer, fallopian tube cancer, advanced or metastatic non-hematologic malignancies including metastatic adenocarcinoma of the pancreas, advanced or metastatic triple-negative breast cancer (TNBC), recurrent and/or metastatic head and neck squamous cell carcinoma, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal carcinoma, platinum-resistant ovarian carcinoma, esophageal carcinoma of adenocarcinoma, soft tissue sarcoma, gastric cancer, metastatic uveal melanoma, metastatic melanoma, non-small cell lung cancer, small-cell lung cancer and solid tumors, pancreatic ductal adenocarcinoma, metastatic colorectal cancer and advanced or metastatic pancreatic cancer. It is a small molecule administered orally. The drug candidate acts on protein tyrosine kinase 2 (focal adhesion kinase). It was under development for non-hematologic malignancies, head and neck cancer and solid tumor.

Inxmed (Nanjing) overview

Inxmed (Nanjing) is a clinical-stage biotech company that focuses to develop therapies targeting stroma microenvironment and solid tumor resistance for drug development in cancer therapies. The company is headquartered in Nanjing, Jiangsu, China.

For a complete picture of Ifebemtinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.